Structure Therapeutics (NASDAQ: GPCR) Anchored the Obesity Runner-Up Narrative With the Phase 2b ACCESS II Trial of Aleniglipron (Once-Daily Oral Small-Molecule GLP-1 Receptor Agonist) That Documented 16.3% Placebo-Adjusted Mean Weight Loss at the 180 mg Dose (39 lbs) and 16.0% Weight Loss at the 240 mg Dose (37 lbs) at 44 Weeks Positioning Aleniglipron as the Highest-Efficacy Oral GLP-1 Agonist Data Reported to Date; The Core Phase 2b ACCESS Study Had Documented 11.3% Weight Loss at 120 mg at 36 Weeks; ACCESS Open-Label Extension (OLE) Study Documented Continued Weight Loss From 36 Weeks Up to 16.2% (40.5 lbs) With 120 mg at 56 Weeks With No Observed Plateau; Tolerability Profile Consistent With the GLP-1 Class With Only 3.7% Adverse-Event-Related Treatment Discontinuation Across All Active Arms at 120 mg or Higher From Weeks 28 to 44; Phase 3 Initiation Expected in H2 2026
Structure Therapeutics (NASDAQ: GPCR) reported detailed Phase 2b ACCESS II trial results for aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist for obesity). Key efficacy: 16.3% placebo-adjusted mean weight loss at the 180 mg dose (39 lbs) and 16.0% weight loss at the 240 mg dose (37 lbs) at 44 weeks. This positions aleniglipron as the highest-efficacy oral GLP-1 agonist data reported to date, above Eli Lilly's orforglipron (Foundayo, 7.5-11.2% at 72 weeks in ATTAIN-1) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg, roughly 15% at 68 weeks in OASIS 4). The core Phase 2b ACCESS study had documented 11.3% placebo-adjusted weight loss at 120 mg at 36 weeks. The ACCESS Open-Label Extension (OLE) study documented continued weight loss from 36 weeks up to 16.2% (40.5 lbs) with 120 mg at 56 weeks with no observed plateau, an important tolerability and durability signal. Tolerability profile is consistent with the GLP-1 receptor agonist class with only 3.7% adverse-event-related treatment discontinuation across all active arms in participants who reached 120 mg or higher from weeks 28 to 44. Phase 3 initiation is expected in H2 2026. Aleniglipron is a non-peptide small molecule that binds the GLP-1 receptor, similar to Lilly's orforglipron but distinct from the peptide-based semaglutide and tirzepatide; the small-molecule format provides manufacturing scalability advantages over peptide APIs.